First Trust Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

First Trust Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.45M	Sell	284,065 -67,152	-19%	-$1.56M	﹤0.01%	1351
2026 Q1	$8.27M	Sell	351,217 -53,437	-13%	-$1.36M	0.01%	1185
2025 Q4	$11.8M	Buy	404,654 +179,689	+80%	+$4.6M	0.01%	1037
2025 Q3	$4.24M	Sell	224,965 -116,556	-34%	-$1.84M	﹤0.01%	1457
2025 Q2	$4.79M	Sell	341,521 -98,664	-22%	-$1.38M	﹤0.01%	1372
2025 Q1	$6.88M	Buy	440,185 +177,048	+67%	+$2.49M	0.01%	1173
2024 Q4	$3.67M	Buy	+263,137	New	+$2.88M	﹤0.01%	1537

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

First Trust Advisors's ARQT Position: Q2 2026 in Review

First Trust Advisors reduced its Arcutis Biotherapeutics (ARQT) stake by 19% in Q2 2026, selling an estimated $1.56M and leaving 284,065 shares worth $7.45M. The position accounts for ﹤0.01% of the portfolio, ranked #1351.

First Trust Advisors first reported a position in ARQT in Q4 2024 and has held it in 7 quarters since. The position peaked at $11.8M in Q4 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

First Trust Advisors held 284,065 shares of Arcutis Biotherapeutics worth $7.45M as of Q2 2026.
First Trust Advisors sold 67,152 Arcutis Biotherapeutics shares in Q2 2026, an estimated $1.56M.
Arcutis Biotherapeutics made up ﹤0.01% of First Trust Advisors's portfolio in Q2 2026, its #1351 holding.
First Trust Advisors first reported a position in Arcutis Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
First Trust Advisors's Arcutis Biotherapeutics position peaked at $11.8M in Q4 2025.
273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.